225 related articles for article (PubMed ID: 36724193)
1. Hmong microbiome ANd Gout, Obesity, Vitamin C (HMANGO-C): A phase II clinical study protocol.
Wen YF; Culhane-Pera KA; Pergament SL; Moua Y; Vue B; Yang T; Lo M; Sun B; Knights D; Straka RJ
PLoS One; 2023; 18(2):e0279830. PubMed ID: 36724193
[TBL] [Abstract][Full Text] [Related]
2. Gout prevalence in the Hmong: a prime example of health disparity and the role of community-based genetic research.
Roman YM; Lor K; Xiong T; Culhane-Pera K; Straka RJ
Per Med; 2021 May; 18(3):311-327. PubMed ID: 33787318
[TBL] [Abstract][Full Text] [Related]
3. Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials.
Takahashi T; Beppu T; Hidaka Y; Hosoya T
Clin Exp Hypertens; 2021 Nov; 43(8):730-741. PubMed ID: 34425059
[No Abstract] [Full Text] [Related]
4. Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial.
Mu Z; Wang W; Wang J; Lv W; Chen Y; Wang F; Yu X; Wang Y; Cheng B; Wang Z
Clin Rheumatol; 2019 Dec; 38(12):3511-3519. PubMed ID: 31410659
[TBL] [Abstract][Full Text] [Related]
5. A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
Perez-Ruiz F; Herrero-Beites AM; Carmona L
Arthritis Rheum; 2011 Dec; 63(12):4002-6. PubMed ID: 21898351
[TBL] [Abstract][Full Text] [Related]
6. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
Gupta MK; Singh JA
Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
[TBL] [Abstract][Full Text] [Related]
8. Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan.
Yu KH; Chen DY; Chen JH; Chen SY; Chen SM; Cheng TT; Hsieh SC; Hsieh TY; Hsu PF; Kuo CF; Kuo MC; Lam HC; Lee IT; Liang TH; Lin HY; Lin SC; Tsai WP; Tsay GJ; Wei JC; Yang CH; Tsai WC
Int J Rheum Dis; 2018 Apr; 21(4):772-787. PubMed ID: 29363262
[TBL] [Abstract][Full Text] [Related]
9. Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout.
Ishikawa T; Takahashi T; Taniguchi T; Hosoya T
Expert Opin Pharmacother; 2021 Aug; 22(11):1397-1406. PubMed ID: 33926357
[TBL] [Abstract][Full Text] [Related]
10. Distinct Gut Microbiota in Patients with Asymptomatic Hyperuricemia: A Potential Protector against Gout Development.
Kim HW; Yoon EJ; Jeong SH; Park MC
Yonsei Med J; 2022 Mar; 63(3):241-251. PubMed ID: 35184426
[TBL] [Abstract][Full Text] [Related]
11. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors.
Dehlin M; Jacobsson L; Roddy E
Nat Rev Rheumatol; 2020 Jul; 16(7):380-390. PubMed ID: 32541923
[TBL] [Abstract][Full Text] [Related]
12. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
13. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Becker MA; Schumacher HR; Espinoza LR; Wells AF; MacDonald P; Lloyd E; Lademacher C
Arthritis Res Ther; 2010; 12(2):R63. PubMed ID: 20370912
[TBL] [Abstract][Full Text] [Related]
14. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
15. Increasing trend of asymptomatic hyperuricemia under treatment with urate-lowering drugs in Japan.
Hakoda M; Kasagi F
Mod Rheumatol; 2019 Sep; 29(5):880-884. PubMed ID: 30175646
[No Abstract] [Full Text] [Related]
16. Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study.
Hosoya T; Sasaki T; Hashimoto H; Sakamoto R; Ohashi T
J Clin Pharm Ther; 2016 Jun; 41(3):298-305. PubMed ID: 27079434
[TBL] [Abstract][Full Text] [Related]
17. Achievement of Target Serum Uric Acid Levels and Factors Associated with Therapeutic Failure among Japanese Men Treated for Hyperuricemia/Gout.
Katayama A; Yokokawa H; Fukuda H; Ono Y; Isonuma H; Hisaoka T; Naito T
Intern Med; 2019 May; 58(9):1225-1231. PubMed ID: 30626825
[TBL] [Abstract][Full Text] [Related]
18. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016.
Chen-Xu M; Yokose C; Rai SK; Pillinger MH; Choi HK
Arthritis Rheumatol; 2019 Jun; 71(6):991-999. PubMed ID: 30618180
[TBL] [Abstract][Full Text] [Related]
19. Febuxostat: a new agent for lowering serum urate.
Keenan RT; Pillinger MH
Drugs Today (Barc); 2009 Apr; 45(4):247-60. PubMed ID: 19499090
[TBL] [Abstract][Full Text] [Related]
20. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
